(Reuters) -OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other ...

Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.

OPKO Health (OPK) and Entera Bio (ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a ...

Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral dual agonist glucagon-like peptide-1 (GLP-1)/glucagon, aiming to provide ...